Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor

European Journal of Pharmacology

Volumn 450, Issue 2, 2002, Pages 115-121

  Van Giersbergen, Paul L M ^a   Gnerre, Carmela ^b   Treiber, Alexander ^a   Dingemanse, Jasper ^a   Meyer, Urs A ^b  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Bosentan; Cytochrome P450 enzyme induction; Glibenclamide; Pregnane X receptor

Indexed keywords

4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (2 HYDROXYPHENOXY) 2,2' BIPYRIMIDIN 4 YL]BENZENESULFONAMIDE; BOSENTAN; CYTOCHROME P450 3A4; DRUG METABOLITE; ENDOTHELIN RECEPTOR ANTAGONIST; GLIBENCLAMIDE; LUCIFERASE; PREGNANE X RECEPTOR; RIFAMPICIN; RO 47 8634; RO 48 5033; RO 64 1056; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CASE REPORT; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; KIDNEY CELL; MONKEY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; REPORTER GENE; TRANSCRIPTION REGULATION;

ANIMALS; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYBURIDE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ENDOTHELIN; RECEPTORS, STEROID; SULFONAMIDES;

EID: 0037162704     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02075-7     Document Type: Article

References (36)

1. Bertilsson G., Heidrich J., Svensson K., Asman M., Jendeberg L., Sydow-Bäckman M., Ohlson R., Postlind H., Blomquist P., Berkenstam A. Identification of a human nuclear receptor defines a new signalling pathway for CYP3A induction. Proc. Natl. Acad. Sci. 95:1998;12208-12213.
2. Binet I., Wallnöfer A., Weber C., Jones R., Thiel G. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 57:2000;224-231.
3. Blumberg B., Sabbagh W., Juguilon H., Bolado J. Jr., van Meter C.M., Ong E.S., Evans R.M. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12:1998;3195-3205.
4. Borcherding S.M., Baciewicz A.M., Self T.H. Update on rifampin drug interactions. II. Arch. Intern. Med. 152:1992;711-716.
5. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., Badesch D.B., Roux S., Rainisio M., Bodin F., Rubin L.J. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 358:2001;1119-1123.
6. Clozel M., Breu V., Gray G.A., Kalina B., Löffler B.-M., Burri K., Cassal J.-M., Hirth G., Müller M., Neidhart W., Ramuz H. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270:1994;228-235.
7. Curi-Pedrosa R., Daujat M., Pichard L., Ourlin J.-C., Clair P., Gervot L., Lesca P., Domergue J., Joyeux H., Fourtanier G., Maurel P. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther. 269:1994;384-392.
8. Diaz D., Fabre I., Daujat M., Saint-Aubert B., Bories P., Michel H., Maurel P. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology. 99:1990;737-747.
9. Dingemanse J., Schaarschmidt D., van Giersbergen P.L.M. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Br. J. Clin. Pharmacol. 53:2002;547.
10. Ellahham S.H., Charlon V., Abassi Z., Calis K.A., Choucair W.K. Bosentan and the endothelin system in congestive heart failure. Clin. Cardiol. 23:2000;803-807.
11. Fattinger K., Funk C., Pantze M., Weber C., Reichen J., Stieger B., Meier P.J. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69:2001;223-231.
12. Flockhart D.A., Oesterheld J.R. Cytochrome P450-mediated drug interactions. Psychopharmacology. 9:2000;43-76.
13. Fuhr U. Induction of drug metabolizing enzymes. Pharmacokinetic and toxicological consequences in humans. Clin. Pharmacokinet. 38:2000;493-504.
14. Ged C., Rouillon J.M., Pichard L., Combalbert J., Bressot N., Bories P., Michel H., Beaune P., Maurel P. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br. J. Clin. Pharmacol. 28:1989;373-387.
15. Gerbal-Chaloin S., Daujat M., Pascussi J.-M., Pichard-Garcia L., Vilarem M.-J., Maurel P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem. 277:2002;209-217.
16. Honkakoski P., Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem. J. 347:2000;321-347.
17. Isom H.C., Georgoff I. Quantitative assay for albumin-producing liver cells after simian virus 40 transformation of rat hepatocytes maintained in chemically defined medium. Proc. Natl. Acad. Sci. U. S. A. 81:1984;6378-6382.
18. Jones S.A., Moore L.B., Shenk J.L., Wisely G.B., Hamilton G.A., McKee D.D., Tomkinson N.C.O., LeCluyse E.L., Lambert M.H., Willson T.M., Kliewer S.A., Moore J.T. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14:2000;27-39.
19. Jönsson A., Chan J.C.N., Rydberg T., Vaaler S., Hallengren B., Cockram C.S., Critchley J.A.J.H., Melander A. Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes. Eur. J. Clin. Pharmacol. 56:2000;711-714.
20. Kiowski W., Sütsch G., Hunziker P., Muller P., Kim J., Oechslin E., Schmitt R., Jones R., Bertel O. Evidence of endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
21. Kliewer S.A., Moore J.T., Wade L., Staudinger J.L., Watson M.A., Jones S.A., McKee D.D., Oliver B.B., Willson T.M., Zetterström R.H., Perlmann T., Lehmann J.M. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 92:1998;73-82.
22. Kyrklund C., Backman J.T., Kivistö K.T., Neuvonen M., Laitila J., Neuvonen P.J. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 68:2000;592-597.
23. Landrum Michalets E. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 18:1998;84-112.
24. Lehmann J.M., McKee D.D., Watson M.A., Willson T.M., Moore J.T., Kliewer S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102:1998;1016-1023.
25. Moore L.B., Parks D.J., Jones S.A., Bledsoe R.K., Consler T.G., Stimmel J.B., Goodwin B., Liddle C., Blanchard S.G., Willson T.M., Collins J.L., Kliewer S.A. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275:2000;15122-15127.
26. Ohnhaus E.E., Park B.K. Measurement of urinary 6-β-hydoxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur. J. Clin. Pharmacol. 15:1979;139-145.
27. Pichard L., Fabre I., Fabre G., Domergue J., Saint Aubert B., Mourad G., Maurel P. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18:1990;595-606.
28. Schuetz E.G., Strom S., Yasuda K., Lecureur V., Assem M., Brimer C., Lamba J., Kim R.B., Ramachandran V., Komoroski B.J., Venkataramanan R., Cai H., Sinal C.J., Gonzalez F.J., Schuetz J.D. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem. 276:2001;39411-39418.
29. Smith D.A. Induction and drug development. Eur. J. Pharm. Sci. 11:2000;185-189.
30. Van Giersbergen P.L.M., Treiber A., Clozel M., Bodin F., Dingemanse J. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin. Pharmacol. Ther. 71:2002;253-263.
31. Watkins R.E., Wisely G.B., Moore L.B., Collins J.L., Lambert M.H., Williams S.P., Willson T.M., Kliewer S.A., Redinbo M.R. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science. 292:2001;2329-2333.
32. Waxman D.J. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 369:1999;11-23.
33. Weber C., Banken L., Birnboeck H., Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J. Clin. Pharmacol. 39:1999;847-854.
34. Weber C., Gasser R., Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab. Dispos. 27:1999;810-815.
35. Weber C., Schmitt R., Birnboeck H., Hopfgartner G., Eggers H., Meyer J., van Marle S., Viischer H.W., Jonkman J.H.G. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J. Clin. Pharmacol. 39:1999;703-714.
36. Xie W., Radominska-Pandya A., Shi Y., Simon C.M., Nelson M.C., Ong E.S., Waxman D.J., Evans R.M. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. 98:2001;3375-3380.